Radius Health (NASDAQ: [[ticker:RDUS]]) of Waltham, MA, a developer of treatments for osteoporosis and cancer, said today it has brought Lorraine Fitzpatrick on board as chief medical officer. Fitzpatrick previously was with GlaxoSmithKline (NYSE: [[ticker:GSK]]) and Amgen (NASDAQ: [[ticker:AMGN]]).
Fitzpatrick joins an executive team that went through a tremendous amount of churn in late 2013 and early 2014 in the months leading up to an IPO attempt. The IPO try was postponed then quickly reinstated, with the deal finally consummated in early June 2014.